Gene expression profiling distinguishes proneural glioma stem cells from mesenchymal glioma stem cells  by Chandran, Uma R. et al.
Genomics Data 5 (2015) 333–336
Contents lists available at ScienceDirect
Genomics Data
j ou rna l homepage: ht tp : / /www. journa ls .e lsev ie r .com/genomics-data /Data in BriefGene expression proﬁling distinguishes proneural glioma stem cells from
mesenchymal glioma stem cellsUma R. Chandran a, Soumya Luthra a, Lucas Santana-Santos a,b, PingMao c,j, Sung-Hak Kim c, MutsukoMinata c,
Jianfeng Li e,g,i, Panayiotis V. Benos a,b, Mao DeWang j, Bo Hu f, Shi-Yuan Cheng f,
Ichiro Nakano c,d, Robert W. Sobol e,g,h,i,⁎
a Department of Biomedical Informatics, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
b Department of Computational and Systems Biology, University of Pittsburgh, Pittsburgh, PA 15213, USA
c Department of Neurological Surgery, The Ohio State University, Columbus, OH 43210, USA
d James Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
e Department of Pharmacology & Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15216, USA
f Department of Neurology&Northwestern Brain Tumor Institute, Center for GeneticMedicine, H. Robert Lurie Comprehensive Cancer Center, NorthwesternUniversity Feinberg School ofMedicine,
Chicago, IL 60611, USA
g University of Pittsburgh Cancer Institute, Hillman Cancer Center, Pittsburgh, PA 15213-1863, USA
h Department of Human Genetics, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA 15216, USA
i University of South Alabama Mitchell Cancer Institute, Mobile, AL 36604, USA
j Department of Neurosurgery, First Afﬁliated Hospital of Medical School, Xi'an Jiaotong University, Xi'an, Shaanxi 710061, China⁎ Corresponding author at: University of South Alabam
E-mail address: rwsobol@health.southalabama.edu (R
http://dx.doi.org/10.1016/j.gdata.2015.07.007
2213-5960/© 2015 The Authors. Published by Elsevier Inca b s t r a c ta r t i c l e i n f oArticle history:
Received 9 July 2015
Accepted 12 July 2015
Available online 14 July 2015
Keywords:
Microarray
Normalization
The Cancer Genome Atlas Project
GlioblastomaTumor heterogeneity of high-grade glioma (HGG) is recognized by four clinically relevant subtypes based
on core gene signatures. However, molecular signaling in glioma stem cells (GSCs) in individual HGG
subtypes is poorly characterized. Previously we identiﬁed and characterized two mutually exclusive GSC
subtypes with distinct activated signaling pathways and biological phenotypes. One GSC subtype presented
with a gene signature resembling Proneural (PN) HGG, whereas the other was similar to mesenchymal
(Mes) HGG. Classical HGG-derived GSCswere sub-classiﬁed as either one of these two subtypes. Differential
mRNA expression analysis of PN and Mes GSCs identiﬁed 5796 differentially expressed genes, revealing a
pronounced correlation with the corresponding PN or Mes HGGs. Mes GSCs displayed more aggressive phe-
notypes in vitro and as intracranial xenografts in mice. Further, Mes GSCs were markedly resistant to radi-
ation compared with PN GSCs. Expression of ALDH1A3 — one of the most up-regulated Mes representative
genes and a universal cancer stem cell marker in non-brain cancers—was associated with self-renewal and
a multi-potent stem cell population in Mes but not PN samples. Moreover, inhibition of ALDH1A3 attenuat-
ed the growth of Mes but not PN GSCs in vitro. Lastly, radiation treatment of PN GSCs up-regulated Mes-
associated markers and down-regulated PN-associated markers, whereas inhibition of ALDH1A3 attenuat-
ed an irradiation-induced gain of Mes identity in PN GSCs in vitro. Taken together, our data suggest that two
subtypes of GSCs, harboring distinct metabolic signaling pathways, represent intertumoral glioma hetero-
geneity and highlight previously unidentiﬁed roles of ALDH1A3-associated signaling that promotes aber-
rant proliferation of Mes HGGs and GSCs. Inhibition of ALDH1A3-mediated pathways therefore might
provide a promising therapeutic approach for a subset of HGGs with the Mes signature. Here, we describe
the gene expression analysis, including pre-processing methods for the data published by Mao and col-
leagues in PNAS [1], integration of microarray data from this study with The Cancer Genome Atlas (TCGA)
glioblastoma data and also with another published study.
The raw CEL ﬁles and processed data were submitted to Gene Expression Omnibus (GEO) under the accession
GSE67089.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).a Mitchell Cancer Institute, 1660 Springhill Avenue, Mobile, AL 36604, USA.
.W. Sobol).
. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Sarganism/cell
line/tissueHuman glioma and normal human neurospheres were derived
from 19 high-grade glioma (HGG) samples, 3 human fetal
brain-derived astrocytes (such as 16wf) and human neural
progenitors — see Table S1 in Mao et al., 2013 [1].x See Table S1 in Mao et al., 2013 [1]
quencer or
array typeAffymetrix Human Genome U219 Arrayata format Raw CEL ﬁles and RMA normalized data
xperimental
factorsGSC (PN vs. Mes) and tumor (GSC) vs. normalxperimental
featuresWe performed transcriptomemicroarray analysis of 27 GSC samples
(triplicate samples) from nine patient-derived GSC cultures, ﬁve
glioma cell lines as well as normal human astrocytes and fetal neural
progenitors (16wf) as the normal controls.onsent Level of consent allowed for reuse if applicable; approved by
Ohio State IRB under NIH guidelines.mple source
locationNakano lab, Department of Neurological Surgery, The Ohio State
University, Columbus, Ohio. Human fetal neural stem cell 16wf
was established at the University of California, Los Angeles [2].
Microarrays experiments and analysis were performed in the
Sobol lab at the University of Pittsburgh Cancer Institute,
Pittsburgh, PA.1. Direct link to deposited data
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE670892. Experimental design, materials and methods
2.1. Glioma tumor-derived neurospheres
All the work related to human tissues was performed at The Ohio
State University under an IRB-proved protocol according to NIH guide-
lines. Glioma and normal neurospheres were derived from 19 HGG
samples, 3 fetal brain-derived astrocytes (such as 16wf) and neural
progenitors (see Table S1 [1]) as described previously [3–6]. Brieﬂy,
freshly resected glioma tumor samples were dissociated into single
cells using both mechanical (gently pipet neurospheres with P1000
pipet tips 4–5 times) and enzymatic methods (TrypLE™ Express;
Invitrogen, San Diego, CA). The dissociated tumor cells were cultured
in DMEM/F12 (Invitrogen) supplemented with B27 (1:50), heparin
(5 mg/ml), bFGF (20 ng/ml) and EGF (20 ng/ml). Growth factors
(bFGF and EGF) were added twice a week. To differentiate GSCs,
neurospheres were cultured in DMEM/F12 supplemented with 10%
FBS for 10 days. Phenotypic characterization of these primary cultures
was performed as described previously [7,8]. The human fetal neural
stem cell sample (16wf) was established at the University of California,
Los Angeles as described previously [2]. All the neurospheres analyzed
in this studywere cultured less than 20 passages. Detailed characteriza-
tion of the neurospheres was performed as previously described [3].2.2. RNA Isolation
Cells were lysed with 1 ml Qiazol lysis reagent. Total RNA was
then extracted and puriﬁed using the Qiagen RNeasy Mini kit (cat#
217004) according to the manufacturer's instructions. After a wash
with buffer RWT followedby twowasheswith buffer RPE, RNAproducts
were eluted from the columnwith 30 μl RNase-free water. For each cell
culture, three independent RNA samples were prepared. RNA quality
was determined using an Agilent 2100 Bioanalyzer at the Cancer
Biomarkers Facility at the University of Pittsburgh Cancer Institute. In
all sample preparations, the average RNA integrity number (RIN) was
greater than 9.0. RNA concentration was determined using a Nanodrop
2000.2.3. Quantitative real time polymerase chain reaction (qRT-PCR)
ImProm-II™ Reverse Transcription System (Promega, Madison, WI)
was used to synthesize cDNA from the resulting RNAs according to the
manufacturer's protocol. The reverse transcribed cDNA was analyzed
by qRT-PCR and GAPDH was used as an internal control. Each qRT-PCR
reaction included 25 μl reaction mixture per well that includes 2 μl
cDNA, 1 μl forward primer (10 μM), 1 μl reverse primer (10 μM), 8.5 μl
of DNase/RNase-free distilled water and 12.5 μl SYBR green reagent
(QIAGEN, Valencia, CA). The following cycles were performed during
DNA ampliﬁcation: program started from heating to 94 °C for 2 min,
then followed by 45 cycles of 94 °C (30 s), 60 °C (30 s) and 72 °C
(40 s), ending with the addition of melt curves as an evaluation of
quality. The primer sequences for various human genes used in this
study include the following: CD133 forward: ACTCCCATAAAGCTGGAC
CC; CD133 reverse: TCAATTTTGGATTCATATGCCTT; Olig2 forward:
CTCCTCAAATCGCATCCAGA; Olig2 reverse: AGAAAAAGGTCATCGGGC
TC; Sox2 forward: ACCGGCGGCAACCAGAAGAACAG; Sox2 reverse:
GCGCCGCGGCCGGTATTTAT; Sox11 forward: GGCGTTAACCAGGTTCTC
AA; Sox11 reverse: TACCACCAATGGCTGCATTA; Notch1 forward:
AGTGTGAAGCGGCCAATG; Notch1 reverse: ATAGTCTGCCAC GCCTCTG;
CD44 forward: CC CAGATGGAGAAAGCTCTG; CD44 reverse: ACTTGGCT
TTCTGTCCTCCA; LYN forward: CTGAACTCAAGTCACCGTGG; LYN
reverse: TCCATCGTCACTCAAGCTGT; WT1 forward: TTAAAGGGAGTTGC
TGCTGG; WT1 reverse: GACACCGTGCGTGTGTATTC; BCL2A1forward:
ATGGATAAGGCAAAACGGAG; BCL2A1 reverse: TGGAGTGTCCTTTCTGGT
CA; Chek1 forward: TTGGGCTATCAATGGAAGAAA; Chek1 reverse:
CCCTTAGAAAGCCGGAAGTC; Chek2 forward: CCTGAGGACCAAGAACCT
GA; Chek2 reverse: TGTCCCTCCCAAACCAGTAG; Rad17 forward: TGCC
TACCAGCTTTATGCCT; Rad17 reverse: AAAGTGTCGCTTCAGAGGGA;
Rad51 forward: CTGAGGGTACCTTTAGGCCA; Rad51 reverse: CTGGTG
GTCTGTGTTGAACG; GAPDH forward: GAAGGTGAAGGTCGGAGTCA;
GAPDH reverse: TTGAG GTCAATGAAGGGGTC; Vimentin forward:
GGAGGACATCTTCGAGCTTC; Vimentin reverse: ATGCCTGAGATGTAGA
TGCG; CDH1 forward: GGAGGAGAGCGGTGGTCAAA; CDH1 reverse:
TGTGCAGCTGGCTCAAGTCAA.
For the qRT-PCR analysis of the DNA damage-repair genes, TaqMan
Gene Expression Assay probes from Life technologies were used and
β-actin (cat# 4352935E) was used as an internal control. Each qRT-
PCR assay was performed in a 20 μl volumewith 4 μl cDNA, 1 μl TaqMan
probe, 10 μl TaqMan® Fast Universal Master Mix (2×) (cat# 4367846)
and 5 μl of DNase/RNase-free distilled water. The reactions were
performed in an ABI StepOnePlus RT-PCR system according to the
manufacturer's protocol. The probe IDs for this study are ATM:
Hs01112307_m1; BRCA1: Hs01556193_m1; BRCA2: Hs00609073_m1;
RAD50: Hs00990023_m1; RAD51: Hs00153418_m1; and CDC25C:
Hs00156411_m1.
2.4. DNA microarray analysis
Comparative analysis of mRNA expression was performed using the
Human U219 Array Strip and the Affymetrix GeneAtlas system, as per
the manufacturer's instructions. Microarray analysis for each of the
cell cultures (in triplicate) was accomplished with 100 ng puriﬁed
total RNA (described above) as the initial material and the correspond-
ing ampliﬁed and labeled antisense RNA (aRNA) using a GeneCHip
3'IVT Express kit (Affymetrix), as described by the manufacturer. The
resulting aRNA was fragmented as described by the manufacturer. The
labeled aRNAs were then mixed with hybridization master mix and
the hybridization cocktails were then denatured at 95 °C for 5 min,
followed by 45 °C for 5 min then kept at 45 °C until applied to the
hybridization tray (GeneAtlas System; 120 μl hybridization cocktail of
a cell culture was transferred into a well of a 4 well hybridization
tray). The array strip was immersed into hybridization cocktail and
incubated in the hybridization station at 45 °C for 16 h. After hybridiza-
tion, the strip was washed and stained in the GeneAtlas Fluidics Station
335U.R. Chandran et al. / Genomics Data 5 (2015) 333–336using the GeneAtlas Hybridization, Wash, and Stain Kit (Affymetrix
#900720) and the intensity of each hybridized probe was generated
using the GeneAtlas™ Imaging Station. Raw .CEL ﬁles from the Human
U219 Array Strip were analyzed using the ‘affy’ package in R Bio-
conductor. The raw data were normalized and summarized using
Robust Multichip Average method (RMA). At this point, each gene is
represented by one or more probe sets. Several ﬁltering steps were
performed to remove uninformative probesets. Probesets expressed at
less than 75 units across all samples are considered as non-expressors
and were removed, but only if a gene had other probe sets that were
expressed at greater than 75 units in at least one sample. If all probesets
for a gene are expressed at less than 75 units across all samples, the
probesets were not removed to avoid removing the gene altogether.
For genes represented by multiple probe sets after ﬁltering, the probe
setwith the highest inter-quartile range (IQR)was selected to represent
the gene. IQR, calculated as the difference between the third and ﬁrst
quartiles, is a descriptive statistic used to summarize the extent of the
spread of the data. This is a robust and widely recommended method
to select the probeset that is most likely to detect differential expression
of a gene [9]. It is important to note that although this probeset ﬁltering
method eliminates the complexity of interpreting results frommultiple
probe sets per gene, it does not address the issue of whether a probeset
is annotated or mapped correctly to a gene. The IQR statistic is notFig. 1. A) Clustering dendrogram of the combined dataset Pre ComBat Normalizationdirectly correlated with probe quality or annotation. Affymetrix probe-
sets may be remapped and re-annotated using a number of published
methods whose results may disagree with the Affymetrix annotations.
These alternate methods were not examined.2.5. Differential expression and pathway analysis
Differentially expressedgenesweredetected betweenmesenchymal
and proneural cells using a t-test. Genes with an FDR value b0.05 were
considered to be differentially expressed. Hierarchical bi-clustering was
performed on all 5,796 differentially expressed genes and 27 samples
by independently clustering samples and genes. Euclidean distance and
average linkagewere used as similaritymetric and clusteringmethod, re-
spectively. Clustering was done using the R statistical package (hclust
function). The purpose of hierarchical bi-clustering was to identify simi-
lar groups and trends between samples and genes in the dataset. Differ-
entially expressed genes were compared to all pathways listed in Kyoto
Encyclopedia of Genes and Genomes (KEGG) and enrichment p-value
was calculated using the Fisher's exact test. This analysis identiﬁes
those pathways, which have a statistically large number of genes in the
differentially expressed set. Pathways that had a p-value less than 0.05
were considered signiﬁcantly enriched. KEGG enrichment analysis was. B) Clustering dendrogram of the combined dataset Post ComBat Normalization.
Table 1
15 PN and 15 MES signature genes from Phillips Paper.
Probe Gene symbol Signature gene
209981_at PIPPIN Proneural
207723_s_at KLRC3 Proneural
227984_at SRRM2 Proneural
219537_x_at DLL3 Proneural
218796_at C20orf42 Proneural
243779_at GALNT13 Proneural
214952_at NCAM1 Proneural
206850_at RRP22 Proneural
204953_at SNAP91 Proneural
214279_s_at NDRG2 Proneural
226913_s_at SOX8 Proneural
232833_at dA201G10.1 Proneural
214762_at ATP6V1G2 Proneural
203146_s_at GABBR1 Proneural
219196_at SCG3 Proneural
205266_at LIF Mesenchymal
235417_at FLJ25348 Mesenchymal
223333_s_at ANGPTL4 Mesenchymal
205547_s_at TAGLN Mesenchymal
202628_s_at SERPINE1 Mesenchymal
201058_s_at MYL9 Mesenchymal
211966_at COL4A2 Mesenchymal
226658_at T1A-2 Mesenchymal
211981_at COL4A1 Mesenchymal
229438_at FAM20C Mesenchymal
201666_at TIMP1 Mesenchymal
209396_s_at CHI3L1 Mesenchymal
215870_s_at PLA2G5 Mesenchymal
211564_s_at RIL Mesenchymal
218880_at FOSL2 Mesenchymal
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package KEGG graph.
2.6. Comparison to TCGA GBM and Phillips HGG dataset
The Cancer Genome Atlas (TCGA) gene expression data (level 3) for
58 mesenchymal and 57 proneural tumors [10] was downloaded from
the TCGA web site (https://tcga-data.nci.nih.gov/docs/publications/
gbm_exp/) on July 10th 2012. TCGA data level 3 is post-normalized
gene-level data, so no further normalization was performed. Since
these are two independent datasets, TCGA data and in-house dataset
were combined using Combat normalization [12]. The ComBat algo-
rithm uses an empirical Bayes approach to adjust for potential batch
effects that are introducedwhile combining data fromdifferent sources.
Data was Z-scored after the removal of batch effects and hierarchical
clustering was performed in R. Pearson correlation between TCGA and
in-house datasets were performed in R (‘cor’ function) to verify that
TCGA and in-house subtype expression proﬁles agree with each other.
As a part of the Phillips high-grade glioma (HGG) study [11], 77
primary HGGs and 23 matched recurrent HGGs were proﬁled on
Affymetrix Human Genome U133A and U133B Arrays. The raw CEL
ﬁles were downloaded from GEO (GSE4271) and RMA normalized
using R. The RMA normalized data from the two chips is then put
together and processed as described in the above section onDNAmicro-
array analysis. As described above, the in-house data set and the Phillips
dataset are combined using ComBat Normalization. Fig. 1 shows how
the batch effect observed when the combined dataset is clustered Pre
Normalization (Fig. 1A) and is adjusted for by ComBat normalization
(Fig. 1B). Once the two datasets are combined, data for the 15 PN and
15MES signature genes from the Phillips paper (Table 1) were extract-
ed and hierarchical clustering was performed in R.3. Discussion
We describe here the gene expression dataset used in the isolation
and characterization of human glioma stem cells that exhibit character-
istics of the different glioma subtypes from which they were isolated.
The presence of the stem cells, which have the potential to drive glioma
to different subtypes, is an important ﬁnding for understanding glioma
tumor initiation and propagation. The publication from which this data
set is derived has been cited in high impact journals; the microarray
data are of high quality andmethodswe describe here will enable com-
parison of this data to other published studies including TCGA.
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